U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT07586046) titled 'Defining the Ablative Dose for Y-90 TARE' on May 07.
Brief Summary: This study is being done to help doctors improve how they treat liver tumors that cannot be removed by surgery or treated with standard ablation techniques. The researchers want to find out the best amount of radiation that needs to be delivered to completely destroy (or ablate) parts of the liver that have cancer.
Study Start Date: May, 2026
Study Type: INTERVENTIONAL
Condition:
HCC - Hepatocellular Carcinoma
Intervention:
OTHER: Yttrium-90 Radiation Segmentectomy (Y90 RS) using glass microspheres
The objective of this study is to define an optimal "ablative ...